Literature DB >> 17468758

The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways.

Tiejun Zhao1, Long Yang, Qiang Sun, Meztli Arguello, Dean W Ballard, John Hiscott, Rongtuan Lin.   

Abstract

Intracellular detection of RNA virus infection is mediated by the RNA helicase RIG-I, which is recruited to mitochondria by the adaptor protein MAVS and triggers activation of the transcription factors NF-kappaB, IRF3 and IRF7. Here we demonstrate that virus-induced activation of IRF3 and IRF7 depended on the NF-kappaB modulator NEMO, which acted 'upstream' of the kinases TBK1 and IKKepsilon. IRF3 phosphorylation, formation of IRF3 dimers and DNA binding, as well as IRF3-dependent gene expression, were abrogated in NEMO-deficient cells. IRF3 phosphorylation and interferon production were restored by ectopic expression of NEMO. Thus, NEMO, like MAVS, acts as an adaptor protein that allows RIG-I to activate both the NF-kappaB and IRF signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17468758     DOI: 10.1038/ni1465

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  157 in total

Review 1.  Deciphering the complexity of Toll-like receptor signaling.

Authors:  Renato Ostuni; Ivan Zanoni; Francesca Granucci
Journal:  Cell Mol Life Sci       Date:  2010-07-31       Impact factor: 9.261

Review 2.  NF-κB addiction and its role in cancer: 'one size does not fit all'.

Authors:  M M Chaturvedi; B Sung; V R Yadav; R Kannappan; B B Aggarwal
Journal:  Oncogene       Date:  2010-12-20       Impact factor: 9.867

3.  PIASy inhibits virus-induced and interferon-stimulated transcription through distinct mechanisms.

Authors:  Toru Kubota; Mayumi Matsuoka; Songxiao Xu; Noriyuki Otsuki; Makoto Takeda; Atsushi Kato; Keiko Ozato
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

4.  Herpes simplex virus 1 tegument protein US11 downmodulates the RLR signaling pathway via direct interaction with RIG-I and MDA-5.

Authors:  Junji Xing; Shuai Wang; Rongtuan Lin; Karen L Mossman; Chunfu Zheng
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

5.  Varicella-zoster virus immediate-early protein ORF61 abrogates the IRF3-mediated innate immune response through degradation of activated IRF3.

Authors:  Huifang Zhu; Chunfu Zheng; Junji Xing; Shuai Wang; Shuping Li; Rongtuan Lin; Karen L Mossman
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

6.  Polyubiquitin conjugation to NEMO by triparite motif protein 23 (TRIM23) is critical in antiviral defense.

Authors:  Kei-ichiro Arimoto; Kenji Funami; Yasushi Saeki; Keiji Tanaka; Katsuya Okawa; Osamu Takeuchi; Shizuo Akira; Yoshiki Murakami; Kunitada Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-19       Impact factor: 11.205

7.  Herpes simplex virus 1 serine/threonine kinase US3 hyperphosphorylates IRF3 and inhibits beta interferon production.

Authors:  Shuai Wang; Kezhen Wang; Rongtuan Lin; Chunfu Zheng
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

8.  Identification of a role for TRIM29 in the control of innate immunity in the respiratory tract.

Authors:  Junji Xing; Leiyun Weng; Bin Yuan; Zhuo Wang; Li Jia; Rui Jin; Hongbo Lu; Xian Chang Li; Yong-Jun Liu; Zhiqiang Zhang
Journal:  Nat Immunol       Date:  2016-10-03       Impact factor: 25.606

9.  Aryl Hydrocarbon Receptor Interacting Protein Targets IRF7 to Suppress Antiviral Signaling and the Induction of Type I Interferon.

Authors:  Qinjie Zhou; Alfonso Lavorgna; Melissa Bowman; John Hiscott; Edward W Harhaj
Journal:  J Biol Chem       Date:  2015-04-24       Impact factor: 5.157

10.  Human T cell lymphotropic virus 1 manipulates interferon regulatory signals by controlling the TAK1-IRF3 and IRF4 pathways.

Authors:  Shunsuke Suzuki; Yue Zhou; Alaa Refaat; Ichiro Takasaki; Keiichi Koizumi; Shoji Yamaoka; Yoshiaki Tabuchi; Ikuo Saiki; Hiroaki Sakurai
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.